Table 1 Characteristics of all serum samples used in this study

All-DILD

60

70 (66–74)

21.9 (19.5–23.8)

37/23

22

65 (58–71)

22.1 (19.1–23.5)

17/5

81

69 (63–73)

21.9 (19.1–23.7)

53/28

DAD/DAD-mixed

20

68 (64–74)

21.7 (19.9–22.9)

17/3

3

69 (62–70)

22.3 (21.8–22.6)

3/0

22^§

68 (62–72)

21.7 (20.3–22.6)

19/3

OP

31

69 (66–74)

22.0 (19.0–23.6)

16/15

2

79 (76–82)

21.5 (20.5–22.6)

2/0

32^§

70 (67–75)

22.0 (19.0–23.6)

18/14

NSIP

9

73 (71–75)

22.5 (20.8–25.3)

4/5

16

63 (59–69)

22.3 (17.9–24.0)

12/4

26^#

69 (61–73)

22.6 (20.1–24.3)

16/10

Other

–

–

–

–

1

50

20.8

0/1

1

50

20.8

0/1

DILD recovery

34

69 (67–74)

22.7 (20.2–24.8)

22/12

17

62 (55–69)

21.8 (18.2–23.8)

12/5

53^#

69 (63–72)

22.7 (19.4–24.1)

35/18

DILD-tolerant

–

–

–

–

–

–

–

–

20

70 (67–72)

21.5 (20.2–23.5)

12/8

Lung cancer

–

–

–

–

–

–

–

–

45

72 (62–76)

21.7 (19.8–25.2)

31/14

BP

–

–

–

–

–

–

–

–

14

66 (64–78)

22.8 (19.3–25.0)

11/3

NTM

–

–

–

–

–

–

–

–

15

74 (71–76)

18.4 (17.4–21.7)

5/10

IIPs

–

–

–

–

–

–

–

–

23

73 (62–76)

23.3 (20.4–25.3)

17/6

CTD

–

–

–

–

–

–

–

–

20

68 (65–70)

23.8 (21.7–26.0)

8/12

COPD

–

–

–

–

–

–

–

–

15

70 (65–76)

21.1 (18.8–23.9)

13/2

BA

–

–

–

–

–

–

–

–

12

60 (51–72)

24.5 (20.5–30.2)

3/9

HC

–

–

–

–

–

–

–

–

30

60 (58–62)

20.6 (20.0–22.9)

15/15